A method for delivery of a pharmaceutical to a subject includes applying a dermal patch to a subject’s skin, wherein the dermal patch comprises a reservoir that stores a pharmaceutical and further comprises at least one hollow needle configured for puncturing the skin, actuating the at least one needle to puncture the subject’s skin, and causing at least a portion of the stored pharmaceutical to be released from the reservoir for delivery via a lumen of the hollow needle to the subject.

A microneedle device of the present invention comprises a substrate, microneedles disposed on the substrate, and a coating layer formed on the microneedles, wherein a length of the microneedles is 300 to 500 μm, the microneedles are disposed on the substrate at a density of 28 to 80 needles/cm.sup.2, and the coating layer comprises a biologically active substance. The microneedle device allows the skin irritation caused by administration of an agent to be reduced.

The present invention relates to devices and methods for providing a triggering mechanism which lowers the trigger force to activate the trigger mechanism to a comfortable range of while still preserving or increasing the speed at which the triggering mechanism accelerates or imparts velocity to a device attached to the triggering mechanism. The present invention further relates to improved applicators for administering microprojection arrays to skin and methods of administering microprojection arrays. In particular, the present invention relates to compact stable self-contained mechanical energy storage for delivery of a medical device such as a microprojection array.

Microneedle electrodes for detecting targets or sensing pH are described. The microneedles may be made of a hydrogel, a probe coupled to the hydrogel for generating an electrochemical signal in the presence of the target, and a conductive material for communicating the electrochemical signal through the hydrogel. The hydrogel microneedles may be used for in-situ detection of targets, such as biomolecules found in interstitial fluid. Also described are methods of producing hydrogel microneedles, articles and apparatus comprising microneedle electrodes, and methods and uses of the same. The microneedle electrodes may be used for biosensing, such as in transdermal patches for detecting biomarkers in a subject. The biosensors may be used for continuous, real-time tracking of targets in-situ, without requiring further reagents or processing steps.

A drug delivery system is described comprising a detachable support and a plurality of drug-loaded transdermal microneedles, for delivering drugs into gingival tissue for the treatment of periodontal disease.

Disclosed herein are aesthetic-enhancing formulations and methods thereof. For example, an aesthetic-enhancing formulation includes, in some embodiments, one or more pigments, one or more active ingredients, and one or more excipients. The one-or-more excipients includes at least a vehicle configured to evenly distribute components throughout the aesthetic-enhancing formulation, the components including the one-or-more pigments, the one-or-more active ingredients, and any other excipients other than the vehicle. In another example, a method for the aesthetic-enhancing formulation includes, in some embodiments, inserting the aesthetic-enhancing formulation into a dermal layer of skin by percutaneous punctures.

A medical drug devices for transdermal drug delivery systems (TDDS) comprising a novel iontophoretic polymeric microneedle device and its use in administration of drugs.

The present invention provides a method for generating an immune response in a subject, comprising administering to the subject's skin an immunizing composition from a SARS-CoV-2 pathogen, wherein the composition is administered with a microneedle delivery device.

The present invention provides methods for determining whether a subject is allergic to an allergen, comprising administering to the subject's skin at an injection site a composition comprising the allergen, wherein the composition is administered with a microneedle delivery device; and monitoring the injection site of the subject's skin for the appearance of a hypersensitivity reaction, wherein the appearance of the hypersensitivity reaction indicates that the subject is allergic to the allergen.

Provided herein are microneedle array devices for delivery of recombinant adenovirus particles, methods of making the devices, and used for the devices. The microneedle array devices are storage-stable at 4° C., retaining adenovirus infectivity for at least one month.